Strategic partnerships are a key part of Diamyd Medical's strategy on the path from a research company to a market oriented diabetes company. Diamyd Medical is seeking partners to help support the commercialization and development of products across the pipeline. Multiple out-licensing and co-development opportunities are available worldwide. Additionally Diamyd is interested in expanding its product portfolio and is actively evaluating in-licensing and acquisition opportunities for therapeutic candidates in the areas of diabetes.
Licensing summary
- Diamyd® for LADA is offered for licensing worldwide
- Diamyd® for type 1 diabetes is offered for licensing in some markets
- Diabetes related NTDDS products are developed to Phase II and then offered for licensing
- Non-diabetes NTDDS products are packaged for early spin-out, e.g. the cancer product NC3
- Entire NTDDS platform could be open for licensing
If you are interested in pursuing a partnership opportunity or would like additional information, please contact the Business Development department.